Bukkuri, Anuraag
Pienta, Kenneth J.
Austin, Robert H.
Hammarlund, Emma U.
Amend, Sarah R.
Brown, Joel S.
Funding for this research was provided by:
National Science Foundation Graduate Research Fellowship Program (1746051)
Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation
National Cancer Institute (U54CA143803, 1U54CA193489-01A1)
US National Science Foundation (PHY-1659940)
ational Science Foundation through the Center for the Physics of Biological Function (PHY-1734030)
Princeton Catalysis Initiative
ParadOX-ERC Starting Grant (96948)
Swedish Research Council (2019-05254)
US Department of Defense CDMRP/PCRP (W81XWH-20-10353)
Article History
Received: 28 February 2022
Accepted: 5 August 2022
First Online: 12 August 2022
Competing interests
: K.J.P. is a consultant for CUE Biopharma, Inc., and holds equity interest in CUE Biopharma, Inc., Keystone Biopharma, Inc. and PEEL Therapeutics, Inc. S.R.A. holds equity interest in Keystone Biopharma, Inc. A.B., R.H.A., E.U.H., and J.S.B. declare no potential conflict of interest.